Intellia Q3 net loss narrows

INTELLIA THERAPEUTICS

06/11/2025 21:11

Overview

Intellia Q3 net loss narrows to $101.3 mln, collaboration revenue rises

FDA places clinical hold on MAGNITUDE trials due to safety concerns

Enrollment completed in Phase 3 HAELO trial, topline data expected mid-2026

Outlook

Company suspends milestone guidance for nex-z pending regulatory alignment

Intellia expects lonvo-z topline data by mid-2026

Company anticipates U.S. commercial launch of lonvo-z in 1H27

Result Drivers

PHASE 3 ENROLLMENT COMPLETED - Enrollment completed in Phase 3 HAELO trial of lonvo-z, topline data expected mid-2026

COLLABORATION REVENUE INCREASE - Collaboration revenue rose due to cost reimbursements from Regeneron Pharmaceuticals

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Collaboration Revenue
$13.78 mln
Q3 Net Income
-$101.32 mln
Q3 Basic EPS
-$0.92
Q3 Operating Expenses
$125.26 mln
Q3 Operating Income
-$111.48 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 9 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Intellia Therapeutics Inc is $24.50, about 44.6% above its November 5 closing price of $13.57

Press Release: ID:nGNX2Yx9mT

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)